Deutetrabenazine

Deutetrabenazine
Clinical data
Trade names	Austedo
Other names	Tetrabenazine D6; SD809; SD-809
AHFS/Drugs.com	Monograph
MedlinePlus	a617022
License data	US DailyMed: Deutetrabenazine;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
ATC code	N07XX16 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ;
Identifiers
	IUPAC name (3R,11bR)-3-(2-Methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one;
CAS Number	1392826-25-3;
PubChem CID	73437646;
DrugBank	DB12161;
ChemSpider	34222717;
UNII	P341G6W9NB;
KEGG	D10701;
Chemical and physical data
Formula	C19H21D6NO3
Molar mass	323.462 g·mol−1

Deutetrabenazine (trade name Austedo) is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia.

Chemically, deutetrabenazine is an isotopic isomer of tetrabenazine in which six hydrogen atoms have been replaced by deuterium atoms. The incorporation of deuterium slows the rate of drug metabolism, allowing less frequent dosing.^[2]^[3]

Efficacy[]

A Lancet study published on June 28, 2017 carried out a review between October 29, 2014 and August 19, 2016 where 298 patients were randomly assigned to receive at least one of the following: one dose of placebo per day, one dose of deutetrabenazine 12 mg/day, one dose of deutetrabenazine 24 mg/day, or one dose of deutetrabenazine 36 mg/day. From baseline to week 12, the least-squares mean AIMS (Abnormal Involuntary Movement Scale) score improved by −3.3 points in the deutetrabenazine 36 mg/day group, −3.2 points in the 24 mg/day group, −2.1 points in the 12 mg/day group, and −1.4 points in the placebo group. Deutetrabenazine 24 mg/day and 36 mg/day provided a significant reduction in tardive dyskinesia, with favourable safety and tolerability. These findings suggest that dosing regimens could be individualized and tailored for patients on the basis of dyskinesia control and tolerability.^[4]

Pharmacology[]

Pharmacodynamics[]

Deutetrabenazine acts as a monoamine-depleting agent.^{[citation needed]}

History[]

Teva Pharmaceuticals received approval from the Food and Drug Administration to market deutetrabenazine in early 2017, along with five years of orphan drug exclusivity for the treatment of chorea associated with Huntington's disease. It was the first deuterated drug to receive FDA approval.^[5]^[6]^[7]

References[]

^ ^a ^b "Austedo". Therapeutic Goods Administration (TGA). 9 June 2021. Retrieved 6 September 2021.
^ Citrome L (April 2016). "Breakthrough Drugs for the Interface Between Psychiatry and Neurology". International Journal of Clinical Practice. 70 (4): 298–9. doi:10.1111/ijcp.12805. PMID 27028671.
^ Coppen EM, Roos RA (January 2017). "Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease". Drugs. 77 (1): 29–46. doi:10.1007/s40265-016-0670-4. PMC 5216093. PMID 27988871.
^ Anderson, Karen E; Stamler, David; Davis, Mat D; Factor, Stewart A; Hauser, Robert A; Isojärvi, Jouko; Fredrik L, Jarskog; Jimenez-Shahed, Joohi; Kumar, Rajeev; McEvoy, Joseph P; Ochudlo, Stanislaw; Ondo, William G; Fernandez, Hubert H (June 28, 2017). "Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial". The Lancet. 4 (8): 595–604. doi:10.1016/S2215-0366(17)30236-5. PMID 28668671. Retrieved February 4, 2018.
^ "FDA Approves Drug for Huntington's Disease". April 3, 2017.
^ Schmidt, C (7 June 2017). "First deuterated drug approved". Nature Biotechnology. 35 (6): 493–494. doi:10.1038/nbt0617-493. PMID 28591114. S2CID 205269152.
^ "FDA Determines that Deuterated Compounds are NCEs and Different Orphan Drugs Versus Non-deuterated Versions". FDA Law Blog. 16 July 2017. Retrieved 5 November 2017.

External links[]

"Deutetrabenazine". Drug Information Portal. U.S. National Library of Medicine.

[Austedo_APM_summary-1] "Austedo". Therapeutic Goods Administration (TGA). 9 June 2021. Retrieved 6 September 2021.

[2] Citrome L (April 2016). "Breakthrough Drugs for the Interface Between Psychiatry and Neurology". International Journal of Clinical Practice. 70 (4): 298–9. doi:10.1111/ijcp.12805. PMID 27028671.

[pmid27988871-3] Coppen EM, Roos RA (January 2017). "Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease". Drugs. 77 (1): 29–46. doi:10.1007/s40265-016-0670-4. PMC 5216093. PMID 27988871.

[DTB_AIMS_Efficacy-4] Anderson, Karen E; Stamler, David; Davis, Mat D; Factor, Stewart A; Hauser, Robert A; Isojärvi, Jouko; Fredrik L, Jarskog; Jimenez-Shahed, Joohi; Kumar, Rajeev; McEvoy, Joseph P; Ochudlo, Stanislaw; Ondo, William G; Fernandez, Hubert H (June 28, 2017). "Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial". The Lancet. 4 (8): 595–604. doi:10.1016/S2215-0366(17)30236-5. PMID 28668671. Retrieved February 4, 2018.

[5] "FDA Approves Drug for Huntington's Disease". April 3, 2017.

[6] Schmidt, C (7 June 2017). "First deuterated drug approved". Nature Biotechnology. 35 (6): 493–494. doi:10.1038/nbt0617-493. PMID 28591114. S2CID 205269152.

[7] "FDA Determines that Deuterated Compounds are NCEs and Different Orphan Drugs Versus Non-deuterated Versions". FDA Law Blog. 16 July 2017. Retrieved 5 November 2017.

[1]

[2]

[3]

[4]

[5]

[6]

[7]